<PAGE> 1
. UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. )*
CELL THERAPEUTICS, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
150934 10 7
(CUSIP Number)
James J. Bergin, Esq.
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
(908) 524-2464
(Name, Address and Telephone Number of Person Authorized to Receive Notices and
Communications)
October 27, 1997
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(b)(3) or (4), check the following box.
NOTE: Six copies of this statement, including all exhibits, should be filed
with the Commission. See Rule 13d-1(a) for other parties to whom copies are
to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
<PAGE> 2
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 10 Pages
<PAGE> 3
SCHEDULE 13D
- --------------------------------- -------------------------------
CUSIP NO. 150934 10 7 PAGE 2 OF 10 PAGES
- --------------------------------- -------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson 22-1024240
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A)
[ ]
(B)
[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
AF
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)
[ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- -------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------------
8 SHARED VOTING POWER
868,262
---------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
868,262
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
868,262
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.65%
- -------------------------------------------------------------------------------
<PAGE> 4
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 5
SCHEDULE 13D
- --------------------------------- -------------------------------
CUSIP NO. 150934 10 7 PAGE 3 OF 10 PAGES
- --------------------------------- -------------------------------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Johnson & Johnson Development Corporation 22-2007137
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A)
[ ]
(B)
[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEMS 2(d) or 2(e)
[ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
- -------------------------------------------------------------------------------
NUMBER OF 7 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH
REPORTING
PERSON
WITH
---------------------------------------------------------------
8 SHARED VOTING POWER
868,262
---------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
868,262
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
868,262
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
[ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.65%
- -------------------------------------------------------------------------------
<PAGE> 6
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
<PAGE> 7
CUSIP NO. 150934 10 7 PAGE 4 OF 10 PAGES
Item 1. Security and Issuer:
Common Stock, no par value ("Common Stock")
Cell Therapeutics, Inc.
201 Elliott Avenue West
Seattle, WA 98119
Item 2. Identity and Background:
(a) Johnson & Johnson ("J&J") and Johnson & Johnson
Development Corporation ("JJDC"), both New Jersey
corporations.
(b) One Johnson & Johnson Plaza, New Brunswick, New
Jersey 08933.
(c) The principal business of J&J is health care
products. JJDC is a wholly-owned subsidiary of J&J
engaged in the venture capital business.
The name, citizenship, residence or business address
and principal occupation or employment (and the name,
principal business and address of any corporation or
other organization in which such employment is
conducted) of each director and executive officer of
J&J and JJDC is set forth on Appendix A hereto.
(d),(e) To the best of J&J's knowledge, neither J&J nor any
of its directors or executive officers has, during
the past five years: (i) been convicted in a criminal
proceeding (excluding traffic violations or similar
misdemeanors) or (ii) been a party to a civil
proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or
final order enjoining future violations of, or
prohibiting or mandating activities subject to,
Federal or State securities laws or finding any
violation with respect to such laws. To the best of
JJDC's knowledge, neither JJDC nor any of its
directors or executive officers has, during the past
five years: (i) been convicted in a criminal
proceeding (excluding traffic violations or similar
misdemeanors) or (ii) been a party to a civil
proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such
proceeding was or is subject to a judgment, decree or
final order enjoining future violations of, or
prohibiting or
<PAGE> 8
CUSIP NO. 150934 10 7 PAGE 5 OF 10 PAGES
mandating activities subject to, Federal or State
securities laws of finding any violation with respect
to such laws.
(f) Not applicable.
Item 3. Source and Amount of Funds or Other Consideration:
On October 27, 1997, JJDC purchased 125,000 shares of Common Stock
($16.00 per share) of Cell Therapeutics, Inc. (the "Company"), in a
fully underwritten and registered, secondary offering. No funds were
borrowed to finance the purchase.
Item 4. Purpose of Transaction:
J&J and JJDC have no present plans or proposals which relate to, or
would result in, any of the actions enumerated in paragraphs (a)
through (j) of this Item.
Item 5. Interest in Securities of the Issuer:
(a) As of October 27, 1997, J&J and JJDC each had
beneficial ownership of an aggregate of 868,262
shares of Common Stock, which constituted
approximately 5.65% of the outstanding shares of
Common Stock of the Company at that time.
(b) J&J and JJDC each have shared power to vote and
shared power to dispose of all shares described in
paragraph (a) above.
(c) Except as described in the response to Item 3 hereof,
there were no transactions in the Common Stock of the
Company effected by J&J or JJDC during the past sixty
days.
To the best knowledge of J&J and JJDC, no director or
executive officer of J&J or JJDC beneficially owns
any shares of Common Stock or other securities of the
Company. Neither J&J nor JJDC is aware of any
transaction in such securities during the past sixty
(60) days by any of its executive officers or
directors.
(d) Not applicable.
(e) Not applicable.
<PAGE> 9
CUSIP NO. 150934 10 7 PAGE 6 OF 10 PAGES
Item 6. Contracts, Arrangements, etc.:
Not applicable.
Item 7. Exhibits:
Not applicable.
<PAGE> 10
CUSIP NO. 150934 10 7 PAGE 7 OF 10 PAGES
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
JOHNSON & JOHNSON
Dated: November 5, 1997 By /s/ P. S. Galloway
------------------------------
Name: Peter S. Galloway
Title: Secretary
JOHNSON & JOHNSON DEVELOPMENT
CORPORATION
Dated: November 5, 1997 By /s/ P.S. Galloway
------------------------------
Name: Peter S. Galloway
Title: Secretary
<PAGE> 11
CUSIP NO. 150934 10 7 PAGE 8 OF 10 PAGES
SCHEDULE A
Board of Directors and Executive Officers of
Johnson & Johnson
The directors and executive officers of Johnson & Johnson are
identified in the table below. Directors of Johnson & Johnson are indicated by
an asterisk.
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
- ---- ---------------- ----------- --------------------
<S> <C> <C> <C>
1. Dr. Gerard N. Burrow (*) Yale New Haven School United Dean of the Yale
of Medicine States University School of
333 Cedar Street Medicine since 1992
New Haven, CT 06510
2. Joan Ganz Cooney (*) Children's Television United Chairman, Children's
Workshop States Television Workshop
One Lincoln Plaza
New York, NY 10023
3. James Cullen (*) Bell Atlantic United Vice Chairman of the
Corporation States Board, Bell Atlantic
1310 North Court House Corporation
Road
Arlington, VA 22201
Johnson & Johnson
4. Robert J. Darretta One Johnson & Johnson United Vice President, Finance
Plaza States and Member, Executive
New Brunswick, NJ Committee of Johnson &
08933 Johnson
5. Russell C. Deyo Johnson & Johnson United Vice President,
One Johnson & Johnson States Administration, and
Plaza Member, Executive
New Brunswick, NJ Committee of Johnson &
08933 Johnson
6. Roger S. Fine Johnson & Johnson United Vice President and
One Johnson & Johnson States General Counsel and
Plaza Member, Executive
New Brunswick, NJ Committee of Johnson &
08933 Johnson
7. Ronald G. Gelbman Johnson & Johnson United Member, Executive
One Johnson & Johnson States Committee of Johnson &
Plaza Johnson
New Brunswick, NJ
08933
8. Philip M. Hawley (*) Philip M. Hawley United Former Chairman and
Suite 2280 States Chief Executive Officer
444 South Flower of Carter Hawley Hale
Street Stores, Inc.
Los Angeles, CA
90071-2900
9. JoAnn H. Heisen Johnson & Johnson United Corporate Vice
One Johnson & Johnson States President, Chief
Plaza Information Officer,
New Brunswick, NJ 08933 and Member, Executive
Committee of Johnson &
Johnson
10. Ann Dibble Jordan (*) Johnson & Johnson United Director of various
One Johnson & Johnson States other corporations
Plaza
New Brunswick, NJ
08933
11. Christian A. Koffmann Johnson & Johnson France Member, Executive
One Johnson & Johnson Committee of Johnson &
Plaza Johnson
New Brunswick, NJ 08933
</TABLE>
<PAGE> 12
CUSIP NO. 150934 10 7 PAGE 9 OF 10 PAGES
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
- ---- ---------------- ----------- --------------------
<S> <C> <C> <C>
12. Arnold G. Langbo (*) 111 Capital Avenue, Canada Chairman of the Board
S.W. and Chief Executive
Battle Creek, MI 49015 Officer of the Kellogg
Company
13. Ralph S. Larsen (*) Johnson & Johnson United Chairman, Board of
One Johnson & Johnson States Directors, Chief
Plaza Executive Officer and
New Brunswick, NJ Chairman, Executive
08933 Committee, of Johnson &
Johnson
14. James T. Lenehan Johnson & Johnson United Member, Executive
One Johnson & Johnson States Committee of Johnson &
Plaza Johnson
New Brunswick, NJ
08933
15. Dr. John S. Mayo (*) AT&T Bell United President, Emeritus,
Laboratories, Inc. States AT&T Bell Laboratories,
600 Mountain Avenue Inc.
Murray Hill, NJ 07974
16. Thomas S. Murphy (*) Capital Cities/ABC, United Former Chairman of the
Inc. States Board and Chief
77 West 66th Street Executive Officer of
New York, NY Capital Cities/ABC
10023-6298
17. Paul J. Rizzo (*) IBM Corporation United Retired Vice Chairman
Old Orchard Road States of International
Armonk, NY 10504 Business Machines
Corporation
18. Henry B. Schact (*) Lucent Technologies United Chairman of the Board
600 Mountain Avenue States of Lucent Technologies
Murray Hill, N.J. 07974
19. Maxine F. Singer, Carnegie Institution United President of the
Ph.D.(*) of Washington States Carnegie Institution of
1530 P Street, N.W. Washington
Washington, D.C.
20005-1910
20. Roger B. Smith (*) Johnson & Johnson United Retired Chairman of
One Johnson & Johnson States General Motors
Plaza Corporation, Member of
New Brunswick NJ 08933 the Business Council
and Trustee of the
Alfred P. Sloan
Foundation
21. Robert N. Wilson (*) Johnson & Johnson United Vice Chairman, Board of
One Johnson & Johnson States Directors and Vice
Plaza Chairman, Executive
New Brunswick, NJ Committee of Johnson &
08933 Johnson
</TABLE>
<PAGE> 13
CUSIP NO. 150934 10 7 PAGE 10 OF 10 PAGES
Board of Directors and Executive Officers of
Johnson & Johnson Development Corporation
The directors and executive officers of Johnson & Johnson
Development Corporation are identified in the table below. Directors of Johnson
& Johnson Development Corporation are indicated by an asterisk.
<TABLE>
<CAPTION>
Name Business Address Citizenship Principal Occupation
- ---- ---------------- ----------- --------------------
<S> <C> <C> <C>
1. Peter S. Johnson & Johnson United Secretary and Associate General
Galloway (*) One Johnson & States Counsel of Johnson & Johnson;
Johnson Plaza and Vice President and
New Brunswick, Secretary of Johnson & Johnson
NJ 08933 Development Corporation
2. Thomas M. Johnson & Johnson United Vice President of
Gorrie, Ph.D. One Johnson & States Johnson & Johnson Development
Johnson Plaza Corporation
New Brunswick,
NJ 08933
3. Susan Lambert Johnson & Johnson United Vice President of
One Johnson & Kingdom Johnson & Johnson Development
Johnson Plaza Corporation
New Brunswick, NJ
08933
4. Alfred T. Mays Johnson & Johnson United President, McNeil Specialty
One Johnson & States Products Company; and Vice
Johnson Plaza President of Johnson & Johnson
New Brunswick, NJ Development Corporation
08933
5. Ting Pau Oei (*) Johnson & Johnson United Vice President of
One Johnson & States Johnson & Johnson Development
Johnson Plaza Corporation
New Brunswick,
NJ 08933
6. James R. Utaski Johnson & Johnson United Corporate Vice President,
(*) One Johnson & States Business Development of Johnson
Johnson Plaza & Johnson; President of Johnson
New Brunswick, & Johnson Development
NJ 08933 Corporation
7. Dr. Brad Vale Johnson & Johnson United Vice President of
One Johnson & States Johnson & Johnson Development
Johnson Plaza Corporation
New Brunswick,
NJ 08933
</TABLE>
